Aspergillosis, Mucormycosis
Conditions
Keywords
Aspergillosis, Mucormycosis, Isavuconazole, Korean
Brief summary
The purpose of this study is to observe safety and effectiveness of Cresemba in patients with invasive Aspergillosis or invasive Mucormycosis in Korea during the post-marketing surveillance period as required by Ministry of Food and Drug Safety (MFDS).
Detailed description
In compliance with the Korean New Drug Re-Examination Guidelines, this study aims to collect further observational data on the safety and effectiveness of Cresemba for six years after authorization is obtained in at least 600 subjects under routine clinical practice. As the safety and effectiveness results obtained from the clinical development program of Cresemba are based on randomized trials using specific inclusion and exclusion criteria, data from the present post-authorization study where Cresemba is used in routine clinical practice per approved label is anticipated to provide important information on safety and effectiveness in a real-world population in Korea. This non-interventional study is designated as a PMS study and is a commitment to MFDS.
Interventions
DRUGIsauvuconazole group
Patients who are treated with Isavuconazole according to its protocol label.
Sponsors
Pfizer
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: * Patients aged 19 years or older * Patients with proven or suspected diagnosis of invasive Aspergillosis or invasive Mucormycosis. * Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion criteria
Patients meeting any of the following criteria will not be included in the study: * Patients with known hypersensitivity to the active substance of Isavuconazole or to any of the excipients. * Patients are ineligible as determined by the investigator, such as those with familial short QT syndrome. * Patients administrating ketoconazole, high-dose ritonavir (\>200 mg every 12 hours) or strong CYP3A4/5 inducers (e.g. rifampicin, carbamazepine, phenytoin) that cannot be discontinued before administration of Cresemba.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse event (AE) as safety evaluation | Starting from administration of first dose of Isavuconazole, will be continued through 28 days after from last administration of Isavuconazole. | Incidence of the adverse events from baseline in all patients who received at least one dose of Isavuconazole and completed safety follow up will be assessed. AEs will be analyzed by preferred term coding. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effectiveness evaluation | From baseline to end of treatment or up to 12 weeks, whichever comes first. | Effectiveness parameters- clinical response will be evaluated. |
Countries
South Korea
Contacts
STUDY_DIRECTORPfizer CT.gov Call Center
Pfizer
Outcome results
None listed